Tapping BlackBerry as part of a push into hospitals is a natural fit for Samsung, particularly because Apple just raised the stakes of the enterprise mobility game by inking a high-profile partnership with IBM, and healthcare was a big part of that push.
All factors worth bearing in mind, certainly, but in a sense this article is simply a reminder that every potential intervention needs to be considered on its merits, and that potentially successful solutions reside in the middle of a complex set of interrelations.
Overlooking any one of them is likely to consign your efforts to failure.
Oh, and good luck with 'interoperability'.
Who can really be said to have 'cracked' this yet, beyond marketing spin?
A 'Gordian Knot' solution that addresses the difficulties of legacy providers' EHR interoperability by severing ties with them altogether, and taking a consumer-led view by using the patient's own healthcare records seems only a generation or two of devices away at this point.
Apple is trying create 'an iPod experience' in healthcare driven by its wearables, but Apple's wearables need to do things significant enough to persuade health consumers to carry their products around with them.
"A patient and carer viewpoint [will be] represented in every single session and workshop throughout the day, [and] we will be involving people with lived experience in other areas across the conference, including as speakers, chairs and mentors."
Andrew Spong's insight:
There are many reasons to want to attend healthcare conferences.
However, when there are options like this available, it's verging on reprehensible for anyone in the pharmaceutical industry to continue to support the lame duck, 'Usual Suspect' digital pharma conferences that reiterate themselves year after year, celebrating their repetition as though having done the same thing for eight years were an achievement rather than an embarrassment.
If you're serious about putting the patient at the centre of what you do, you *have* to go to conferences that put the patient at the centre of their programme -- not ones that pay lip service to 'patient engagement' in the absence of their eponymous subjects, and brazenly focus on patients as 'targets' and 'opportunities' rather than as people.
Bayer, Boehringer Ingelheim, Genentech (Roche), GSK, Novartis and Sanofi have been shortlisted as finalists in the 'Digital pharmaceutical company of the year' category of this year's PM Society Digital Media Awards
Andrew Spong's insight:
I was pleased that STweM was able to work with our partners Symplur to compile the data behind this year's 'Digital pharmaceutical company of the year' category.
Results were derived by collating all tweets published in 2013 using the top ten hashtags in Symplur's Healthcare Hashtag Project associated with ten leading causes of mortality.
The top pharma companies within each disease area were identified according to the frequency with which they were mentioned.
The final results were determined by subsequently identifying those companies which featured most often in each category, weighting by rank, and ordering accordingly.
The winner will be announced on 25 September. I was kindly asked to present the award by the PM Society, but will be out of the country. PM Society co-chair Carwyn Jones has graciously offered to do the honours in my absence.
The evergreen question of what constitutes 'ROI' for pharma in being seen to actively participate in the healthcare conversation on the social web around conference is addressed from many angles in this @CancerGeek article, which reflects on Thomas Lee of Symplur's recent MedX presentation.
Do also be sure to read the productive exchanges in the comments.